Yazar "Keskinoglu, A." seçeneğine göre listele

Listeleniyor 1 - 7 / 7
  • Küçük Resim Yok
    Öğe
    Clinical experience of everolimus in pediatric renal transplant recipients
    (Springer, 2011) Dincel, N.; Kara, O. D.; Keskinoglu, A.; Sen, S.; Hoscoskun, C.; Kabasakal, C.; Mir, S.
  • Küçük Resim Yok
    Öğe
    Cytomegalovirus Experience in Pediatric Kidney Transplantation in 26 Years’ Time
    (Elsevier Inc., 2020) Keskinoglu, A.; Bulut, İ.K.; Taner, S.; Turkes, A.Z.; Kabasakal, C.
    Introduction: In this study,we investigated the presence of cytomegalovirus (CMV) infection in kidney transplanted children and its effect on kidney dysfunction. Material and Methods: One hundred thirty-five pediatric renal transplant patients were included in this study. The presence of CMV infection, CMV risk status, and other clinical features of the patients were evaluated retrospectively. Results: Fifty-three percent of all patients and 68.8% of patients with CMV were male. The mean age was 12 years in all patients and CMV groups. According to the CMV risk classification, 40.9% of the patients with CMV infection/disease were in the high-risk group (CMV D+R-). In CMV risk groups, the presence of CMV infection/disease was similar. Cold ischemia time, male sex (patients and donors), deceased donor, higher HLA-mismatches, and cumulative antithymocyte globulin dose were found as risk factors for CMV infection/disease. Acute rejection/graft failure was observed in 27% of all patients. CMV infection has no effect on rejection/graft failure and survival. Discussion: The frequency and risk factors of CMV in renal transplant children in our study were consistent with the literature. Conclusions: CMV infection was found in one-fifth of our patients and the majority (71.9%) of them developed infection in the first 6 months. In one-third of our patients acute rejection/graft failure was observed. There was no effect of CMV infection on rejection/graft failure and survival in pediatric patients with proper and effective treatment. © 2020
  • Küçük Resim Yok
    Öğe
    The Factors Effecting Graft Survey in Pediatric Renal Recipients: A Single Center Study
    (Springer, 2010) Sozeri, B.; Kara, O. D.; Dincel, N.; Keskinoglu, A.; Kabasakal, C.; Hoscoskun, C.; Mir, S.
  • Küçük Resim Yok
    Öğe
    The importance of antibiotic prophylaxis in management of VUR
    (Springer, 2007) Yavascan, O.; Mir, S.; Mutlubas, F.; Keskinoglu, A.; Yilmaz, E.; Bulut, I.; Anik, A.
  • Küçük Resim Yok
    Öğe
    Inhibitory effects of mesenchymal stem cells on lymphoblastic leukemia cell proliferation
    (Wiley-Blackwell, 2013) Cetintas, V. B.; Aktug, H.; Oltulu, F.; Keskinoglu, A.; Del Castello, B. E.; Taskiran, D.
  • Küçük Resim Yok
    Öğe
  • Küçük Resim Yok
    Öğe
    Long-Term Follow-up Results of Renal Transplantation in Pediatric Patients With Focal Segmental Glomerulosclerosis: A Single-Center Experience
    (Elsevier Science Inc, 2019) Bulut, I. K.; Taner, S.; Keskinoglu, A.; Toz, H.; Sarsik, B.; Sezer, T. O.; Kabasakal, C.
    Introduction and Aim. Focal segmental glomerulosclerosis (FSGS) is a common cause of end-stage renal disease in children. We analyzed the long-term outcome of pediatric patients with FSGS undergoing renal transplantation. the objective of the study is to report the experience of a single center and determine the incidence of recurrence, rejection, graft loss, and related risk factors. Materials and Method. This retrospective cohort study was performed between 1991 and 2018. Thirty patients with a pathologic diagnosis of primary FSGS were included in the study. the patients were diagnosed with FSGS according to histologic features in biopsies. Results. Twenty-one of the donors were deceased (70%) and 9 were alive (30%). FSGS recurred in only 2 patients. Graft loss occurred in 6 patients (20%). the causes of graft loss were chronic rejection in 4 patients and acute rejection in 2. Our graft survival rate was 100% at 1 year, 91% at 5 years, 80% at 10 years, 70% at 15 years, and 42% at 20 years. Five- and 10-year graft survival rates were 83% and 83% in living donors and 94% and 79% in deceased donors, respectively. According to Kaplan-Meier analysis, there was no statistically significant difference in terms of graft survival between living and deceased donors. Conclusion. This study, with its contribution to literature in terms of long follow-up of FSGS patients from childhood to adulthood, is important. However, further studies are required.